Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CFO Dominic Piscitelli sold 14,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total transaction of $189,420.00. Following the completion of the transaction, the chief financial officer owned 69,828 shares in the company, valued at approximately $944,772.84. This trade represents a 16.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dominic Piscitelli also recently made the following trade(s):
- On Monday, September 28th, Dominic Piscitelli sold 13,400 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.53, for a total transaction of $181,302.00.
- On Thursday, September 24th, Dominic Piscitelli sold 600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.50, for a total transaction of $8,100.00.
- On Wednesday, August 26th, Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00.
Oric Pharmaceuticals Price Performance
ORIC stock traded up $0.07 during midday trading on Wednesday, reaching $13.85. The company had a trading volume of 1,568,523 shares, compared to its average volume of 1,688,164. Oric Pharmaceuticals, Inc. has a 1 year low of $7.23 and a 1 year high of $14.68. The company has a market capitalization of $1.44 billion, a P/E ratio of -10.26 and a beta of 0.99. The firm has a 50-day moving average price of $12.94 and a 200-day moving average price of $10.94.
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). On average, equities analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. WINTON GROUP Ltd bought a new stake in shares of Oric Pharmaceuticals in the 2nd quarter worth approximately $899,000. Engineers Gate Manager LP purchased a new stake in shares of Oric Pharmaceuticals in the 2nd quarter valued at $694,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Oric Pharmaceuticals in the 2nd quarter valued at $38,000. Squarepoint Ops LLC purchased a new stake in shares of Oric Pharmaceuticals in the 2nd quarter valued at $3,729,000. Finally, AXQ Capital LP bought a new position in shares of Oric Pharmaceuticals during the 2nd quarter valued at $396,000. 95.05% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts recently commented on ORIC shares. Leerink Partners assumed coverage on Oric Pharmaceuticals in a research note on Monday, October 5th. They issued an “outperform” rating and a $26.00 target price on the stock. HC Wainwright raised their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, August 10th. BTIG Research began coverage on Oric Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “buy” rating and a $26.00 price target for the company. Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Fourteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Oric Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.17.
Get Our Latest Report on Oric Pharmaceuticals
About Oric Pharmaceuticals
Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.
Oric’s pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.
Recommended Stories
- Five stocks we like better than Oric Pharmaceuticals
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
